Edoxaban monotherapy reduces adverse events compared to dual therapy in patients with atrial fibrillation and coronary artery disease.

This study represents a secondary analysis of a randomized clinical trial involving 1,040 patients diagnosed with atrial fibrillation and stable coronary artery disease. The specific setting of the trial was not reported in the available data. The primary objective was to assess the impact of atrial fibrillation pattern on the efficacy and safety of different antithrombotic strategies. The population included patients managed with either edoxaban monotherapy or dual antithrombotic therapy, which consisted of edoxaban combined with a single antiplatelet agent. The follow-up period for the analysis was 12.0 months.

The primary outcome measured was net adverse clinical events, defined as a composite of all-cause death, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, major bleeding, or clinically relevant nonmajor bleeding. The analysis specifically investigated whether the pattern of atrial fibrillation—categorized as paroxysmal or nonparoxysmal—influenced the outcomes associated with the chosen treatment strategy. The study found that the rate of the primary outcome was similar between patients with paroxysmal atrial fibrillation and those with nonparoxysmal atrial fibrillation when comparing the two treatment approaches.

Regarding the primary outcome rates by treatment strategy, edoxaban monotherapy was associated with a significantly lower risk of net adverse clinical events compared to dual antithrombotic therapy. In patients with paroxysmal atrial fibrillation, the primary outcome occurred in 4.6% of those on monotherapy versus 16.2% of those on dual therapy, with an adjusted hazard ratio of 0.23 (95% CI, 0.12-0.42). In patients with nonparoxysmal atrial fibrillation, the rates were 9.3% for monotherapy versus 15.0% for dual therapy, with an adjusted hazard ratio of 0.56 (95% CI, 0.32-0.87). The analysis also examined the interaction between antithrombotic strategy and atrial fibrillation pattern, finding no significant interaction (p=0.10).

Safety and tolerability findings were not reported in the provided data, nor were specific adverse event rates, serious adverse events, discontinuation rates, or general tolerability metrics available for review. Consequently, a detailed assessment of the safety profile beyond the composite bleeding and death endpoints included in the primary outcome is not possible based on the current information. The study did not report specific adverse event rates or discontinuations due to adverse events.

The available data does not provide specific details on how these results compare to prior landmark studies in the therapeutic area of atrial fibrillation and coronary artery disease management, nor does it explicitly address funding sources or potential conflicts of interest. Methodological limitations and potential biases were not detailed in the provided text. The study design was a secondary analysis of an RCT, which inherently limits the ability to draw new causal conclusions distinct from the primary trial's findings.

Clinically, these results suggest that for patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy may offer a reduction in net adverse clinical events compared to dual antithrombotic therapy, regardless of whether the atrial fibrillation is paroxysmal or nonparoxysmal. This finding supports the consideration of monotherapy to simplify treatment regimens and potentially reduce bleeding risks, although the absence of reported safety data limits the full assessment of tolerability. Further questions remain regarding long-term safety profiles not captured in this 12-month analysis and the generalizability of these findings to broader populations not included in this specific secondary analysis.